Cambridge-based gene therapy developer bluebird bio said today it has been awarded $9.3 million from the California Institute for Regenerative Medicine to support a Phase 1\/2 study for the companys product LentiGlobin, which is designed to treat a group of inherited blood disorders. <\/p>\n
The study will be initiated in the United States next year. <\/p>\n
LentiGlobin introduces a full functional human beta-globin gene into the patients own hematopoietic stem cells, which ultimately produce fully functioning red blood cells. The company is currently conducting a Phase 1\/2 trial examining the feasibility, safety and efficacy of LentiGlobin in treating beta-thalassemia and sickle cell disease. <\/p>\n
The CIRM award is among the first awards under the agencys Strategic Partnership Awards initiative, which is designed to engage more effectively with industry and increase outside investment in CIRM-funded stem cell research. <\/p>\n<\/p>\n
See the rest here:<\/p>\n
Bluebird bio lands $9.3M for study<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Cambridge-based gene therapy developer bluebird bio said today it has been awarded $9.3 million from the California Institute for Regenerative Medicine to support a Phase 1\/2 study for the companys product LentiGlobin, which is designed to treat a group of inherited blood disorders. The study will be initiated in the United States next year. Continue reading